Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis

…, U Jacob, M Krumbholz, T Kuempfel, A Blaschek… - Neurology, 2011 - AAN Enterprises
Objective: To study the longitudinal dynamics of anti–myelin oligodendrocyte glycoprotein (MOG)
autoantibodies in childhood demyelinating diseases. Methods: We addressed the …

Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome

…, K Schanda, B Anlar, B Bajer-Kornek, A Blaschek… - Neurology, 2017 - AAN Enterprises
Objective: To assess the prognostic value of MOG antibodies (abs) in the differential
diagnosis of acquired demyelinating syndromes (ADS). Methods: Clinical course, MRI, MOG-abs, …

Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein

…, U Gruber-Sedlmayr, A Blaschek… - Journal of Neurology …, 2015 - jnnp.bmj.com
Background Myelin oligodendrocyte glycoprotein (MOG) antibodies have been recently
described in children with acute disseminating encephalomyelitis (ADEM), but the clinical and …

Monogenic variants in dystonia: an exome-wide sequencing study

…, A Sitzberger, S Schröder, A Blaschek… - The Lancet …, 2020 - thelancet.com
Background Dystonia is a clinically and genetically heterogeneous condition that occurs in
isolation (isolated dystonia), in combination with other movement disorders (combined …

Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an …

…, W Müller-Felber, K Vill, A Blaschek… - The Lancet Child & …, 2022 - thelancet.com
Background Given the novelty of gene replacement therapy with onasemnogene abeparvovec
in spinal muscular atrophy, efficacy and safety data are limited, especially for children …

Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica

…, V Gredler, A Guenther, A Blaschek… - Multiple sclerosis …, 2013 - journals.sagepub.com
Background: Recently we showed that antibodies to myelin oligodendrocyte glycoprotein (MOG)
can be found in aquaporin-4 (AQP4)-immunoglobulin (IgG) seronegative pediatric and …

[HTML][HTML] Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years

K Vill, O Schwartz, A Blaschek, D Gläser… - Orphanet journal of rare …, 2021 - Springer
Background Spinal muscular atrophy (SMA) is the most common neurodegenerative disease
in childhood. Since motor neuron injury is usually not reversible, early diagnosis and …

Anti–myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis

…, M Karenfort, D Tibussek, A Blaschek… - Archives of …, 2012 - jamanetwork.com
Objective To study the humoral immune response directed at myelin oligodendrocyte
glycoprotein (MOG) in pediatric patients with isolated and recurrent optic neuritis (ON). Design …

[HTML][HTML] Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric …

…, A Merkenschlager, C Thiels, A Blaschek… - Journal of …, 2020 - Springer
Background New-generation, cell-based assays have demonstrated a robust association of
serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) …

Genetic predisposition in anti‐LGI1 and anti‐NMDA receptor encephalitis

…, F Thaler, C Muth, I Borggräfe, A Blaschek… - Annals of …, 2018 - Wiley Online Library
We performed a genome‐wide association study in 1,194 controls and 150 patients with anti‐N‐methyl‐D‐aspartate
receptor (anti‐NMDAR, n = 96) or anti‐leucine‐rich glioma‐…